Product Information
AMLODIPINE-ATORVAST 10-10 MG is a generic product labeled by Mylan Pharmaceuticals Inc., priced at $0.9795 per EA under NDC 00378451793. Its NADAC has been published 616 times since Dec 17, 2014.
FDA first approved this application on Nov 29, 2013. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
10; 10 mg/1; mg/1
Manufacturer
Mylan Pharmaceuticals Inc.NDC
00378451793
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM TRIHYDRATEApproval Type
Generic (ANDA)
FDA Application
ANDA200465FDA Approved
11/29/2013
TE Code
AB
On Market Since
11/6/2014
Pharmacological Classes
Price Statistics
The NADAC for AMLODIPINE-ATORVAST 10-10 MG has been published 616 times since Dec 17, 2014, and over the history we have for it it has declined 74.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.9795 per EA |
|---|---|
| All-time high | $5.1337 (Jul 15, 2015) |
| All-time low | $0.6894 (Jul 17, 2024) |
| 52-week high | $1.6115 |
| 52-week low | $0.9795 |
| Median price | $2.4749 |
| Average price | $2.4713 |
| Largest weekly change | +65.6% (Feb 22, 2023) |
| Weeks tracked | 616 |
| Tracking since | Dec 17, 2014 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Amlodipine and atorvastatin market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Mylan Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Amlodipine and atorvastatin market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Calcium Channel Blocker class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of AMLODIPINE-ATORVAST 10-10 MG?
The current National Average Drug Acquisition Cost (NADAC) for AMLODIPINE-ATORVAST 10-10 MG, manufactured by Mylan Pharmaceuticals Inc., is $0.9795 per EA (NDC 00378451793), effective Sep 30, 2026.
How has the price of AMLODIPINE-ATORVAST 10-10 MG changed over time?
Over the history we have for it, the NADAC for AMLODIPINE-ATORVAST 10-10 MG has declined 74.7%. It has been tracked across 616 weekly CMS publications since Dec 17, 2014.
What are the highest and lowest recorded NADAC prices for AMLODIPINE-ATORVAST 10-10 MG?
Since Dec 17, 2014, the NADAC for AMLODIPINE-ATORVAST 10-10 MG has ranged from a low of $0.6894 (Jul 17, 2024) to a high of $5.1337 (Jul 15, 2015), with a median of $2.4749 per EA.
Are there cheaper alternatives to AMLODIPINE-ATORVAST 10-10 MG?
No other NADAC-published product currently shares the active ingredient and strength of AMLODIPINE-ATORVAST 10-10 MG in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures AMLODIPINE-ATORVAST 10-10 MG?
AMLODIPINE-ATORVAST 10-10 MG (NDC 00378451793) is labeled by Mylan Pharmaceuticals Inc., and CMS classifies it as a generic product.